Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.060
+0.010 (0.49%)
At close: Aug 18, 2026, 4:00 PM EDT
2.097
+0.037 (1.82%)
After-hours: Aug 18, 2026, 6:00 PM EDT

BDTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-70----
Revenue Growth
------
Gross Profit
-70----
Selling, General & Admin
16.4316.5727.4727.1128.3930.04
Research & Development
28.1333.5651.3159.3564.4496.83
Operating Expenses
44.5650.1378.7886.4692.83126.87
Operating Income
-44.5619.87-78.78-86.46-92.83-126.87
Interest & Investment Income
4.294.062.181.922.033.46
Earnings From Equity Investments
-----2.25-
Currency Exchange Gain (Loss)
------0
Other Non Operating Income (Expenses)
4.284.513.140.920.18-
EBT Excluding Unusual Items
-35.9828.44-73.46-83.62-92.87-123.41
Gain (Loss) on Sale of Investments
0.771.283.781.17-0.54-2.19
Gain (Loss) on Sale of Assets
----2.23-
Asset Writedown
-7.35-7.35----
Pretax Income
-42.5622.37-69.68-82.44-91.17-125.6
Net Income
-42.5622.37-69.68-82.44-91.17-125.6
Net Income to Common
-42.5622.37-69.68-82.44-91.17-125.6
Net Income Growth
------
Shares Outstanding (Basic)
575755443636
Shares Outstanding (Diluted)
575855443636
Shares Change
0.22%4.61%25.19%21.00%0.38%9.97%
EPS (Basic)
-0.740.39-1.27-1.88-2.51-3.47
EPS (Diluted)
-0.740.39-1.27-1.88-2.51-3.47
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-32.8429.61-62.3-66.75-85.27-102.86
Free Cash Flow Per Share
-0.570.51-1.13-1.52-2.35-2.84
Gross Margin
-100.00%----
Operating Margin
-28.39%----
Profit Margin
-31.95%----
Free Cash Flow Margin
-42.31%----
EBITDA
-44.3520.2-78.44-86.02-92.32-126.67
EBITDA Margin
-28.85%----
D&A For EBITDA
0.210.330.340.440.510.21
EBIT
-44.5619.87-78.78-86.46-92.83-126.87
EBIT Margin
-28.39%----
SEC Filings: 10-K · 10-Q